Retatrutide – otherwise known as ‘triple-G’, ‘GLP-3’ or ‘reta’ – is here. And people can’t get enough of it.
The internet is full of users sharing their experiences with their new favourite peptide – progress updates on Reddit, advice on Instagram and explainers on YouTube.
Why is it so popular? Well, retatrutide seems to shift fat extremely quickly. In clinical trials, participants lost, on average, nearly 30 per cent of their body weight in 18 months, making it around twice as effective as Wegovy, one of the current crop of weight-loss drugs.
“In a world of already huge weight loss, retatrutide looks to be a really substantive jump in efficacy,” says Prof Giles Yeo, an obesity scientist at the University of Cambridge.
It’s no surprise, then, that this powerful weight-loss jab has been met with such enthusiasm.
There’s just one catch: retatrutide hasn’t been approved for use by any country’s regulatory agency yet and, right now, can’t be bought legally.
As the web celebrates the arrival of reta, here’s why you shouldn’t rush to join the party.
Why retatrutide is already here
Have a quick scroll through social media and you’d be forgiven for thinking that doctors have been prescribing retatrutide to anyone who wants it for months.
The Reddit thread r/Retatrutide is full of one-, three- and even 12-month weight-loss journeys credited to the drug. For Yeo, these posts are a cause for alarm.
“Is this real?” he asks. “How the hell are they getting their hands on it? Is it a black market? And how do we even know it’s retatrutide?”
The drug’s manufacturer Eli Lilly states on its website: “Retatrutide has not been approved by any regulatory agency and is legally available only through Lilly’s clinical trials. Anything sold to consumers outside of those trials is illegal, with no way to verify its safety, purity or dosing.”
But that hasn’t stopped vials of liquid labelled as retatrutide from being sold in the US.
In fact, an investigation by CBS News from June 2026 found more than 120 websites that were selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals.
Meanwhile, data from US poison control centres (quoted in the CBS report) suggests a surge of cases attributed to drugs sold as retatrutide in the first four months of 2026, up 265 per cent compared to the last four months of 2025.
Yeo says: “If someone is selling you something called retatrutide, then either they’ve stolen it or it’s something else – both of which are dangerous. No one should be able to get access to these drugs at the moment, except in a trial-centre situation.”
Dr Simon Cork, a senior lecturer in physiology at Anglia Ruskin University, adds that these injectables may not be retatrutide at all, saying: “If you’re buying a drug outside a very regulated market, you don’t know what you’re getting or what you’re putting in your body.”
But, he continues, even if the drugs in question are retatrutide, that doesn’t mean they’re safe to use. “You don’t know what the side effects are until you’ve tested it in a population,” says Cork. “We just don’t know what the risks are yet.”
Read more:
- This is the easiest weight-loss hack nutrition scientists wish everyone knew
- Doctors keep missing a hidden problem with weight loss drugs, Cambridge professor warns
- Ozempic made rapid weight loss easier. But here’s when keeping body fat is healthier, according to doctors
Why reta is particularly dangerous
What we do know is that retatrutide isn’t just another weight-loss drug. It’s nicknamed ‘Godzilla Ozempic’ for a reason – because it’s stronger than anything that’s come before.
The first generation of this class of drug, called incretins, was already revolutionary. People who needed to lose weight for health reasons, but struggled to do it through diet and exercise, could now drop 15 per cent of their body weight in little more than a year.
But Cork says: “Wegovy, which was the blockbuster drug when it came out, is now one of the least effective.”
That’s because Wegovy and Ozempic are single incretin drugs. They use an ingredient called semaglutide to mimic one naturally occurring appetite hormone, in this case GLP-1.
But we now have dual incretins, drugs that target two appetite hormones – GLP-1 and a similar hormone called GIP, at once. Namely, Mounjaro and Zepbound contain tirzepatide. Head-to-head trials show that tirzepatide is more effective than semaglutide, capable of producing 20 per cent weight loss in less than a year and a half.
Enter retatrutide, a triple incretin. It targets GLP-1, GIP and another hormone called glucagon – hence the ‘triple-G’ nickname.
“Dual and triple incretins attack fat from more than one direction,” says Dr Adam Collins, associate professor of nutrition at the University of Surrey. “You’re not just getting a bigger hammer to hit it with. You’re using two or three different mechanisms, which all complement each other, like a hammer and chisel.”
In this way, Collins says, GLP-1 acts on the gut and brain to suppress appetite. GIP works in synergy with GLP-1 to slow the rate at which your stomach empties. And glucagon manages your fat stores, encouraging your body to burn more fat.
The result is dramatic weight loss, on average 28 per cent, according to clinical trials.
Yeo says: “30 per cent of body weight is a lot of body weight. And remember, these are averages. Some people lose 40–50 per cent of their body weight. So, you can lose an awful lot of weight on retatrutide.”
That’s great for people who really need to lose a lot of weight quickly. But retatrutide’s unprecedented strength also makes it more dangerous for those who don’t need it.
“My biggest fear about this entire class of drugs is that they have no starting weight limit to which they work,” says Yeo. “They’ll suppress your appetite when you’re 300lb (140kg), or if you’re 75lb (35kg).”
That means, for anyone using this drug without legal medical supervision, retatrutide represents a serious risk.
Yeo adds: “For people with eating disorders or body dysmorphia, semaglutide was already dangerous. Retatrutide could be even more dangerous.”
Good news for those who need it
These warnings aren’t the whole story, though. For those who need to lose a lot of weight quickly for the sake of their health, retatrutide could be a lifeline when it’s approved.
“If you’re dangerously overweight, then something like semaglutide or tirzepatide may not have got you down to a healthy weight,” says Yeo. “You don’t continue losing weight until you disappear. At some point, you reach a plateau.
“Then, maybe retatrutide is for you because retatrutide is approaching bariatric surgery levels of weight loss – which some people need.”
Retatrutide may also prove helpful to people who didn’t respond to single or dual incretins or who experienced unpleasant side effects.
Cork says: “There might be slight differences in tolerability and side effects. So, that’s a good thing.”
And, thanks to glucagon, retatrutide might be particularly beneficial to people with fat accumulation around their organs, especially those with fatty liver disease.
In a small trial including people with fatty liver disease, 86 per cent of participants reached normal liver fat levels after five and a half months on the highest dose of retatrutide. That doesn’t mean they were cured, but it’s a promising sign.
“I think the interesting thing about glucagon is to do with fat, because it can reduce liver fat in quite a pronounced way,” says Collins. “That might have other benefits, too – your blood cholesterol, for example, could be improved.”
Again, all of this is still being investigated so we can’t say with certainty exactly what retatrutide can do. But we do know it’ll add to an already successful group of weight-loss drugs.
“A lot of people need to lose more weight than can be achieved with diet and exercise, but aren’t large enough to warrant metabolic surgery,” Collins says.
“Some people need something pretty drastic to help them lose weight as quickly as possible, to target underlying health conditions that need to be reversed through weight loss. These drugs are catering to that.”
Indeed, in Cork’s opinion, these weight-loss drugs are “a scientific success story” and “the single most important medical breakthrough in the last 20 years.”
Retatrutide, then, is expected to be extremely useful for those who need it. But it isn’t approved for use yet. And until it is, it shouldn’t be available to anyone outside of a clinical trial.
As such, anything on sale now that’s claiming to be this very powerful drug is potentially dangerous to anyone who chooses to use it.
In short, just like its namesake from the movies, this Godzilla is not something you want to mess around with.
Read more:
